Source-grounded facts extracted from Keros Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Keros Therapeutics, Inc. shareholders approved Advisory vote on executive compensation. at the 2026-06-03 meeting.
“The Company’s stockholders approved, on a non-binding advisory basis, Proposal 3. The votes cast were as follows: Votes For Votes Against Votes Abstain Broker Non-Votes 14,273,625.27 974,049 2,038 2,243,514”
Keros Therapeutics, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026. at the 2026-06-03 meeting.
“The Company’s stockholders approved Proposal 2. The votes cast were as follows: Votes For Votes Against Votes Abstain 16,708,279.27 783,953 994 There were no broker non-votes with respect to Proposal 2.”
Keros Therapeutics, Inc. shareholders approved Election of two nominees for director to hold office until the Company's 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. at the 2026-06-03 meeting.
“The Company’s stockholders elected the two persons listed below as directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows: Nominee Votes For Votes Withheld Broker Non-Votes Jean-Jacques Bienaimé 10,093,559.27 5,156,153 2,243,514 Charles Newton 14,716,598 533,114 2,243,514”
Jean-Jacques Bienaimé was appointed as Lead Independent Director at Keros Therapeutics, Inc..
“the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.”
Carl L. Gordon resigned as Chair of the Board at Keros Therapeutics, Inc..
“Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.”
Christopher Rovaldi was appointed as President and Chief Operating Officer at Keros Therapeutics, Inc..
“The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.”
Keros Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income net loss of $43.1 million.
“Keros reported a net loss of $43.1 million in the first quarter of 2024 as compared to a net loss of $35.8 million in the first quarter of 2023.”
Simon Cooper resigned as Chief Medical Officer at Keros Therapeutics, Inc..
“On February 29, 2024, Simon Cooper, M.B.B.S., resigned from his position as Chief Medical Officer of Keros Therapeutics, Inc. (the “Company”), effective March 12, 2024, to pursue other opportunities.”
Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $0.2 million for the year ended December 31, 2023, net income a net loss of $40.2 million for the fourth quarter and $153.0 million for the year ended December 31, 2023.
“Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.